Astrana Health, Inc. (NASDAQ:ASTH) Receives $56.17 Average Target Price from Analysts

Astrana Health, Inc. (NASDAQ:ASTH) has been given a consensus rating of “Moderate Buy” by the ten research firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $53.29.

A number of brokerages have commented on ASTH. Robert W. Baird reduced their price objective on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Bank of America decreased their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus dropped their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Macquarie raised shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Finally, Barclays began coverage on shares of Astrana Health in a research report on Tuesday. They issued an “equal weight” rating and a $36.00 price target on the stock.

Institutional Trading of Astrana Health

A number of institutional investors and hedge funds have recently modified their holdings of ASTH. Vanguard Group Inc. grew its stake in Astrana Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 4,685,959 shares of the company’s stock valued at $147,748,000 after purchasing an additional 20,757 shares during the period. State Street Corp bought a new position in Astrana Health during the third quarter valued at about $91,966,000. Dimensional Fund Advisors LP increased its holdings in Astrana Health by 10.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company’s stock worth $32,968,000 after buying an additional 101,192 shares during the last quarter. Geode Capital Management LLC bought a new stake in Astrana Health in the third quarter worth about $58,995,000. Finally, 325 Capital LLC boosted its stake in Astrana Health by 30.3% in the fourth quarter. 325 Capital LLC now owns 886,916 shares of the company’s stock valued at $27,964,000 after acquiring an additional 206,009 shares during the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Stock Performance

Shares of ASTH stock opened at $30.02 on Thursday. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a 52 week low of $23.12 and a 52 week high of $63.20. The firm has a 50 day moving average of $33.47 and a 200-day moving average of $41.49. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. On average, equities analysts forecast that Astrana Health will post 1.15 earnings per share for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.